Overview

Phase I Study of Progerinin in Healthy Volunteers

Status:
Completed
Trial end date:
2021-07-27
Target enrollment:
Participant gender:
Summary
PRG-PRO-001 is a Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose (SAD) Study including a food interaction study, followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers. This is a first-in-human study. The study aims to determine the safety and tolerability of Progerinin after single and multiple doses in healthy volunteers and to evaluate the pharmacokinetics (PK) of Progerinin after single and multiple dose administrations in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
PRG Science & Technology Co., Ltd.
Collaborator:
Amarex Clinical Research